undamentalytics Newsletter
Sign in

Sunshine Biopharma Inc. (SBFM) stock

Add to watchlist

Add holding +

NASDAQ: SBFM Nasdaq Pharmaceuticals

C Fundamentals grade

Sunshine Biopharma Inc. is a US-listed company in the pharmaceuticals industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Fair value per share

Under review: every model's value for Sunshine Biopharma Inc. is far from the share price, which usually points to a data problem (a merger, a share-count change, a one-off) rather than a bargain or a bubble.

Price vs value

Under review: cash-flow, stock-pay or share-count figures missing or out of date. We'll show the comparison once resolved.

Sunshine Biopharma Inc. valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Funds9 adding, 0 cuttingOf 0 active managers that changed their stake, 0 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter Sunshine Biopharma files

Where Sunshine Biopharma stands after its latest 10-Q

Revenue for the twelve months to June 2026 was $35m, down 2.7% on a year earlier, a steeper fall than the 2.0% decline a quarter earlier. That puts it 38 of 47 for growth among the pharmaceuticals companies we cover. Free-cash-flow margin rose to -15.2% from -23.4% a year earlier. Against its peers on growth, profitability, cash generation and balance sheet, it grades C. It passes 2 of our 2 financial-health checks.

Our model value for Sunshine Biopharma is under review, so past values are not shown until it is resolved.

Source: 10-Q filed August 13, 2026 on SEC EDGAR · Financials · Valuation

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Sunshine Biopharma Inc.'s trailing-twelve-month revenue fell 2.7% year on year, with a free-cash-flow margin of -15.2%. Where it stands out: days sales outstanding of 42 days ranks 9 of 59 pharmaceuticals companies we cover. Where it lags: gross margin of 30.3% ranks 49 of 59 pharmaceuticals companies we cover.

Current signal Free cash flow diverging from earnings: TTM free cash flow grew 36.9% while net income grew 7.5%: a 29pp divergence.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Net cash. Cash exceeds long-term debt by $0.0bn.

Things to watch

  • Revenue shrinking. Revenue fell 2.7% over the last 12 months.
  • Loss-making. Operating margin is -16.6%: costs exceed revenue.
  • Burning cash. Free cash flow was -15.2% of revenue over the last 12 months.
  • Share dilution. Diluted shares rose 55.7% in a year.
  • Volatile shares. Over the past year the shares showed annualised volatility of 166% and a beta of 1.1 against the S&P 500.
  • Gross margin slipping. Gross margin is down 3.0 points on a year ago.

Latest results: FY2026 Q2

Filed August 13, 2026
Earnings per share
-$23.00 against an average estimate of -$24.00: beat by 4.2%
Revenue
$9m, down 1.6% on a year earlier

Sunshine Biopharma's figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day-6.1%
  • 1 week+3.8%
  • 1 month-79.4%
  • This year-98.9%
  • 1 year-99.2%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$35.3M
Operating margin
-16.6%
Net margin
-16.5%
EPS (TTM, diluted)
$-19.90

Growth

Revenue growth
−2.7%
Change in growth rate
−0.7 pts

Cash

Free cash flow (TTM)
-$5.4M
FCF margin
-15.2%

Earnings

Last results
April 9, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Shareholder vote
  2. Agreement
  3. Shareholder vote
  4. Announcement
  5. Leadership
  6. Announcement
  7. Agreement
  8. Agreement

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Sunshine Biopharma Inc. valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: cash-flow, stock-pay or share-count figures missing or out of date.

The inputs used by the models below have passed source checks. Individual model values are available below and in the interactive valuator. Their differences are shown explicitly; the platform combined value and recommendation remain withheld.

Valuation models

We value Sunshine Biopharma Inc. as an operating company, with every model that fits that kind of business. Cost of equity 9.9%: the 10-year Treasury yield (4.9%) plus a beta of 1.09 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. — Does not apply: This model is withheld pending its input or assumption review.
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: This model is withheld pending its input or assumption review.
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: This model is withheld pending its input or assumption review.
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. — Does not apply: This model is withheld pending its input or assumption review.
Price-to-sales vs peers Sales per share times peers' typical price-to-sales; used only when earnings are negative. ~$0.1 ~$15–$65 Left out: out of range vs price (0.02x)
Combined value Individual source-checked model scenarios are available. The platform combined value and recommendation remain withheld. — Combined value withheld. Review the individual models and their assumptions.

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Sunshine Biopharma Inc. with Pharmaceuticals in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Valuation multiples over time Market data may be delayed

At fiscal year end 2022202320242025
Share price$256000.00$108800.00$600.00$246.00
Market value$3.89tn$1.4bn$421m$1.0bn
+ Net debt (− = net cash)−$22m−$16m−$10m−$9m
Enterprise value$3.89tn$1.4bn$411m$1.0bn
Multiples
Price / sales n/m57.9x12.1x28.2x
Price / earnings ————
Price / free cash flow ————
EV / EBITDA ————

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

15 /100

Weak moat

How hard Sunshine Biopharma's competitive advantage looks for rivals to wear away, judged from 10 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 0 / 20

    Net income has been a median -102.7% of total assets over 10 years.

  • Pricing power 5 / 20

    Gross margin has been a median 36.8%, moving by 20.3 percentage points (standard deviation) across 9 years.

  • Durability 10 / 20

    Operating margin has been a median -659.8%; its worst year was -19170.8%.

  • Cash conversion 0 / 20

    Free cash flow was positive in 0 of 5 years, at a median -38.0% of revenue.

  • Discipline 5 / 20

    The diluted share count rose 12996.4% over five years.

AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (20 before it).

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current −$39.00 +87% $37m +1%
Next −$8.00 +80% $45m +22%

Next year's EPS estimate has moved −300.0% in 90 days, across 1 analysts.

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is −69.0% on 90 days ago. In the last 30 days, 1 analyst raised Sunshine Biopharma Inc.'s forecast and 0 cut it.

Consensus EPS forecast Sunshine Biopharma Inc., last 90 days
−$150.00 −$100.00 −$50.00 $0.00 $50.00 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: −$126.00 Current fiscal year, 60 days ago: −$126.00 Current fiscal year, 30 days ago: −$126.00 Current fiscal year, 7 days ago: −$126.00 Current fiscal year, Now: −$39.00 −$39.00 Next fiscal year, 90 days ago: $4.00 Next fiscal year, 60 days ago: $4.00 Next fiscal year, 30 days ago: $4.00 Next fiscal year, 7 days ago: $4.00 Next fiscal year, Now: −$8.00 −$8.00

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago −$126.00$4.00
60 days ago −$126.00$4.00
30 days ago −$126.00$4.00
7 days ago −$126.00$4.00
Now −$39.00−$8.00

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 −$24.00 −$23.00 +4.2%
Mar 2026 −$32.00 −$50.00 −56.2%
Dec 2025 −$54.00 −$92.00 −70.4%
Sept 2025 −$26.00 −$38.00 −46.2%

Adjusted EPS as companies report it, against the average analyst estimate.

Analyst recommendations

1 analysts, Oct 2026
Buy1100%
Hold00%
Sell00%

Monthly trend

  1. Oct 202611

Counts of recommendations published by analysts covering Sunshine Biopharma Inc., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
5.5%
of tradable shares
Days to cover
0.06
at average volume
Short interest, 1 month
+3494%
to October 15, 2026
Held by institutions
8%
of shares
Held by insiders
6.4%
of shares
Employees
50
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

Return and risk by year

Calendar year 2023202420252026 to date
Return
SBFM−58%−99%−59%−99%
Industry peers (median)−13%−2%+9%−12%
S&P 500+26%+25%+18%+11%
Months that ended higher
SBFM17%33%33%0%
S&P 50067%75%75%46%
Largest fall from a high during the year
SBFM−81%−100%−65%−99%
S&P 500−10%−8%−19%−9%

Worst fall since February 15, 2022: 100% from April 7, 2022 to October 26, 2026. Getting back needed a 145660277% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$2.65 – $358.00
From 52-week high
−99.2%
vs 50-day average
−80.0%
vs 200-day average
−97.5%
Volatility (1 year)
167%
Beta vs S&P 500
1.06

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
4 up, 6 down
typical move ±11.2%
After a week
3 up, 7 down
typical move ±15.3%
After a month
3 up, 7 down
typical move ±24.6%
Results releasedNext dayS&P 500 next day5 days21 days
April 9, 2026 −5.0% +0.5% −4.0% 0.0%
May 19, 2025 −0.3% −0.2% −4.7% −1.7%
April 2, 2025 −11.5% −4.3% −28.8% −34.1%
November 7, 2024 +0.4% +1.2% −4.1% +11.2%
August 19, 2024 +2.1% +0.8% +0.3% +2.4%
May 22, 2024 −7.9% −1.0% −18.6% −56.6%
April 1, 2024 +34.4% −0.8% +59.0% −85.7%
November 13, 2023 −8.3% +1.8% −6.9% −17.0%
August 11, 2023 −3.8% +0.5% −7.1% −31.7%
May 11, 2023 +37.9% −0.3% +19.4% +6.0%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Sunshine Biopharma Inc. in five measures

Fundamentals grade C
Growth Profitability Cash Balance sheet

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) Sunshine Biopharma Inc.
$20M $25M $30M $35M $40M FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue (TTM), FY23 Q3: $20.4M Revenue (TTM), FY23 Q4: $24.1M Revenue (TTM), FY24 Q1: $26.7M Revenue (TTM), FY24 Q2: $30.5M Revenue (TTM), FY24 Q3: $33M Revenue (TTM), FY24 Q4: $34.9M Revenue (TTM), FY25 Q1: $36.2M Revenue (TTM), FY25 Q2: $36.3M Revenue (TTM), FY25 Q3: $37.3M Revenue (TTM), FY25 Q4: $36.3M Revenue (TTM), FY26 Q1: $35.5M Revenue (TTM), FY26 Q2: $35.3M $35.3M

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue (TTM)
FY23 Q3 $20.4M
FY23 Q4 $24.1M
FY24 Q1 $26.7M
FY24 Q2 $30.5M
FY24 Q3 $33M
FY24 Q4 $34.9M
FY25 Q1 $36.2M
FY25 Q2 $36.3M
FY25 Q3 $37.3M
FY25 Q4 $36.3M
FY26 Q1 $35.5M
FY26 Q2 $35.3M
Revenue growth, TTM YoY Sunshine Biopharma Inc.
-2000% 0% 2000% 4000% 6000% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue growth, TTM YoY, FY23 Q3: 4046.1% Revenue growth, TTM YoY, FY23 Q4: 454.4% Revenue growth, TTM YoY, FY24 Q1: 193.3% Revenue growth, TTM YoY, FY24 Q2: 109.8% Revenue growth, TTM YoY, FY24 Q3: 61.9% Revenue growth, TTM YoY, FY24 Q4: 44.7% Revenue growth, TTM YoY, FY25 Q1: 35.5% Revenue growth, TTM YoY, FY25 Q2: 19.2% Revenue growth, TTM YoY, FY25 Q3: 13.2% Revenue growth, TTM YoY, FY25 Q4: 4.1% Revenue growth, TTM YoY, FY26 Q1: -2.0% Revenue growth, TTM YoY, FY26 Q2: -2.7% -2.7%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue growth, TTM YoY
FY23 Q3 4046.1%
FY23 Q4 454.4%
FY24 Q1 193.3%
FY24 Q2 109.8%
FY24 Q3 61.9%
FY24 Q4 44.7%
FY25 Q1 35.5%
FY25 Q2 19.2%
FY25 Q3 13.2%
FY25 Q4 4.1%
FY26 Q1 -2.0%
FY26 Q2 -2.7%
Operating margin (TTM) Sunshine Biopharma Inc.
-150% -100% -50% 0% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Operating margin (TTM), FY23 Q3: -132.6% Operating margin (TTM), FY23 Q4: -20.0% Operating margin (TTM), FY24 Q1: -16.2% Operating margin (TTM), FY24 Q2: -15.0% Operating margin (TTM), FY24 Q3: -14.9% Operating margin (TTM), FY24 Q4: -16.5% Operating margin (TTM), FY25 Q1: -15.8% Operating margin (TTM), FY25 Q2: -17.9% Operating margin (TTM), FY25 Q3: -17.3% Operating margin (TTM), FY25 Q4: -17.2% Operating margin (TTM), FY26 Q1: -17.8% Operating margin (TTM), FY26 Q2: -16.6% -16.6%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Operating margin (TTM)
FY23 Q3 -132.6%
FY23 Q4 -20.0%
FY24 Q1 -16.2%
FY24 Q2 -15.0%
FY24 Q3 -14.9%
FY24 Q4 -16.5%
FY25 Q1 -15.8%
FY25 Q2 -17.9%
FY25 Q3 -17.3%
FY25 Q4 -17.2%
FY26 Q1 -17.8%
FY26 Q2 -16.6%
FCF margin (TTM) Sunshine Biopharma Inc.
-20000% -15000% -10000% -5000% 0% FY19 Q2 FY24 Q2 FY25 Q1 FY26 Q2 FCF margin (TTM), FY19 Q2: -17453.3% FCF margin (TTM), FY19 Q3: -4500.6% FCF margin (TTM), FY19 Q4: -2351.5% FCF margin (TTM), FY24 Q2: -38.0% FCF margin (TTM), FY24 Q3: -39.4% FCF margin (TTM), FY24 Q4: -40.7% FCF margin (TTM), FY25 Q1: -34.9% FCF margin (TTM), FY25 Q2: -23.4% FCF margin (TTM), FY25 Q3: -19.8% FCF margin (TTM), FY25 Q4: -15.2% FCF margin (TTM), FY26 Q1: -16.6% FCF margin (TTM), FY26 Q2: -15.2% -15.2%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period FCF margin (TTM)
FY19 Q2 -17453.3%
FY19 Q3 -4500.6%
FY19 Q4 -2351.5%
FY24 Q2 -38.0%
FY24 Q3 -39.4%
FY24 Q4 -40.7%
FY25 Q1 -34.9%
FY25 Q2 -23.4%
FY25 Q3 -19.8%
FY25 Q4 -15.2%
FY26 Q1 -16.6%
FY26 Q2 -15.2%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-Q, 10-Q/A. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2017 Dec 2017 2018 Dec 2018 2019 Dec 2019 2020 Dec 2020 2021 Dec 2021 2022 Dec 2022 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025 LTM Jun 2026
Income
Revenue 0 0 0 0 0 4 24 35 36 35
Gross profit 0 0 0 0 0 2 8 11 12 11
EBITDA −1 −1 −1 −1 −2 −27 −5 −6 −6 −6
Operating income −1 −1 −1 −1 −2 −27 −5 −6 −6 −6
Net income −1 −2 −2 −3 −12 −27 −5 −5 −6 −6
Diluted EPS — — — — −$9520.00 −$1.76 −$351.36 −$7.32 — —
Growth (year on year)
Revenue — — — +238.1% +219.9% +>999% +454.4% +44.7% +4.1% −2.7%
Margins
Gross margin — — 47.7% 63.8% 48.4% 39.0% 34.6% 30.6% 33.8% 30.3%
EBITDA margin — — <−999% −788.1% <−999% −620.8% −19.2% −16.0% −16.2% −15.7%
Operating margin — — <−999% −807.8% <−999% −621.3% −19.9% −16.7% −17.2% −16.6%
Net margin — — <−999% <−999% <−999% −615.4% −18.7% −14.7% −16.5% −16.5%
Free-cash-flow margin — — <−999% −922.1% −800.8% −125.2% −36.8% −40.7% −15.2% −15.2%
Cash flow
Cash from operations −1 −1 −0 −1 −2 −5 −9 −13 −5 −5
Capital spending 0 0 0 0 0 0 0 2 0 0
Free cash flow −1 −1 −0 −1 −2 −5 −9 −14 −6 −5
Stock-based pay 1 1 0 0 — — — — — —
Free cash flow after stock pay −1 −1 −1 −1 — — — — — —
Balance sheet
Cash 0 0 0 1 2 22 16 10 9 14
Total debt 1 1 1 2 2 0 0 0 0 0
Net debt (negative = net cash) 0 1 1 1 −0 −22 −16 −10 −9 −14
Diluted shares 44m 3m 11m 1m 3m 15m — — 4m —
Returned to shareholders
Buybacks — — — — — — 1 3 0 —
Total returned — — — — — — 1 3 0 —

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

2 of 2 checks passed · June 30, 2026
What it owns · $34m
Short-term assets $31mLonger-term assets $3m
What it owes, and who funded it · $34m
Short-term liabilities $6mLonger-term liabilities $0mShareholders' equity $28m
  • Short-term assets cover short-term liabilities $31m of assets due within a year against $6m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $31m short-term assets against $475,820 of longer-dated liabilities.
  • More cash than debt Cash or debt not separately reported. Not assessable.
  • Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
  • Operating profit covers interest at least five times over Interest not separately reported. Not assessable.

From Sunshine Biopharma Inc.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

FY2025 Q4 TTM
Buybacks (TTM)
$0
Returned to shareholders
0%
of free cash flow
Buybacks, last 3 fiscal years
$3.7M
R&D spending
0.7%
of revenue
Days sales outstanding
42 days
receivables vs revenue

Competitors: side by side with peers

Closest by revenue in pharmaceuticals
Last 12 months unless stated SBFM BGM IMCC SCLX CPIX VRCA Median
Revenue, last 12 months $35m $38m $39m $32m $40m $30m $276m
Revenue growth, last 12 months −2.7% 51.1% −0.7% −28.5% −5.2% 106.2% 9.9%
Revenue growth, 3-year average 34.5% — — −12.0% −0.6% 52.2% 5.5%
Revenue growth, latest quarter −1.6% — — −22.8% −18.8% −53.8% 6.5%
Gross margin 30.3% 16.6% 17.7% 55.5% 82.9% 63.8% 62.0%
Operating margin −16.6% −33.2% −21.2% <−999% −24.1% −93.6% −5.9%
Operating margin, 3-year average −16.5% — — −512.2% −19.0% −312.8% −7.4%
Net margin −16.5% −52.6% −20.7% <−999% −27.4% −102.8% −7.3%
Cash from operations / revenue −15.1% −6.3% 8.6% −54.1% 1.9% −44.0% 10.2%
Free-cash-flow margin −15.2% −10.4% 8.6% −70.7% 1.7% −44.0% 8.6%
Free-cash-flow margin, 3-year average −25.5% — — −2.8% 5.4% −280.0% 7.4%
Stock pay / revenue — 27.0% 0.0% 51.0% 1.1% 11.6% 3.6%
Change in share count 55.7% >999% 71.3% — 1.5% 5.6% 1.9%

Median of all 75 companies we cover in pharmaceuticals. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

75 pharmaceuticals companies
Measure Company Peer median Rank
Revenue growth Growth -2.7% 10.0% 56 of 74
Change in growth rate Growth -0.7pp -0.3pp 39 of 74
Gross margin Profitability 30.3% 59.8% 49 of 59
Operating margin Profitability -16.6% -5.9% 41 of 67
Net margin Profitability -16.5% -7.3% 47 of 75
Free-cash-flow margin Cash generation -15.2% 10.1% 56 of 74
Days sales outstanding Balance sheet 42 days 72 days 9 of 59

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Who owns it

Funds buying and selling
Reported value
$32,615
Institutions reporting
9
Positions opened / closed
9 / 0

Top buyers and sellers, Q2 2026: 9 institutions bought and 0 sold ; the biggest buyer was Jane Street Group, LLC (+15K shares) . See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Jane Street Group, LLC $31,445 15K 96.4% —
Morgan Stanley $808 0K 2.5% —
Sbi Securities Co., Ltd. $340 0K 1.0% —
National Bank Of Canada $10 0K 0.0% —
Osaic Holdings, Inc. $4 0K 0.0% —
Strive Financial Group ,Llc $2 0K 0.0% —
Caitong International Asset Management Co., Ltd $2 0K 0.0% —
TD Waterhouse Canada Inc. $2 0K 0.0% —
Farther Finance Advisors, LLC $2 0K 0.0% —

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Sunshine Biopharma Inc.'s complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $0 0 trades by 0 insiders
Net ▲ $0 net buying

No open-market insider trades reported in the last 12 months.

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Trades by members of Congress

All 1 trade and filings

No trades in Sunshine Biopharma Inc. disclosed in the last 12 months; 1 earlier trade on record.

  • Roger Williams(R-TX 25):Purchase, $1,001 - $15,000, traded June 30, 2022, filed June 12, 2024

Value ranges as filed; reports can arrive up to 45 days after a trade.

Earnings dates and SEC filings

Results announcements

Next expected around July 10, 2026 estimated from the company's past filing pattern, not announced

  • April 9, 2026
  • May 19, 2025
  • April 2, 2025
  • November 7, 2024
  • August 19, 2024
  • May 22, 2024

Recent SEC filings

Data status

When each part of this page on Sunshine Biopharma Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Sunshine Biopharma Inc. in brief

What does Sunshine Biopharma Inc. do?
Sunshine Biopharma Inc. is a US-listed company in the pharmaceuticals industry. Its financial year ends in December.
What is Sunshine Biopharma Inc.'s stock ticker?
Sunshine Biopharma Inc. trades under the ticker SBFM on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Sunshine Biopharma Inc.'s revenue, and how fast is it growing?
Over its most recent trailing twelve months, Sunshine Biopharma Inc. reported revenue of $35.3M, 2.7% lower than a year earlier, according to its SEC filings.
What is Sunshine Biopharma Inc.'s free cash flow?
Sunshine Biopharma Inc.'s free-cash-flow margin is -15.2% of revenue over the trailing twelve months, ranking 56 of the 74 pharmaceuticals companies we cover.
Who are Sunshine Biopharma Inc.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Jane Street Group, LLC, Morgan Stanley and Sbi Securities Co., Ltd. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
What is Sunshine Biopharma Inc.'s market cap?
On December 31, 2025, Sunshine Biopharma Inc.'s market capitalisation was about $1B and net debt of -$9.1M. Market figures come from third-party market data and may be delayed.
Who are Sunshine Biopharma Inc.'s competitors?
In our Pharmaceuticals peer group, the companies closest to Sunshine Biopharma Inc. are BGM Group Ltd., IM Cannabis Corp., Scilex Holding Co, Cumberland Pharmaceuticals Inc and Verrica Pharmaceuticals Inc. The side-by-side comparison below sets their revenue, margins and growth against Sunshine Biopharma Inc.'s.